When evaluating treatment options for prostate cancer, patients often search to understand the length of treatment procedures and recovery times….
Ten patients received therapy, with an initial response seen in 7 out of 9 evaluable patients to date. Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.
Dr. Michael K. Schultz, Chief Scientific Officer at Perspective Therapeutics, presented research at the WWIC on the potential of lead-based targeted alpha particle therapy using [212Pb]VMT-α-NET for the treatment of neuroendocrine tumors (NETs)…
Prostate cancer is the most common cancer and the second leading cause of cancer death among men in the United States…
©2023. All rights reserved. Terms & Privacy | Privacy Policy
